Epoetin alfa (Binocrit®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32012000382
English
Authors' recommendations:
Epoetin alfa (Binocrit®) is recommended as an option for restricted use within NHS Wales in accordance with NICE Clinical Guideline 39 for the treatment of symptomatic anaemia associated with chronic renal failure in adult and paediatric patients:
- Treatment of anaemia associated with chronic renal failure in paediatric and adult patients on haemodialysis and adult patients on peritoneal dialysis.
- Treatment of severe anaemia of renal origin accompanied by clinical symptoms in adult patients with renal insufficiency not yet undergoing dialysis.
Epoetin alfa (Binocrit®) is not suitable for shared care within NHS Wales for the above indications.
Epoetin alfa (Binocrit®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Details
Project Status:
Completed
Year Published:
2010
URL for published report:
http://www.wales.nhs.uk/sites3/docmetadata.cfm?orgid=371&id=162708&pid=24773
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Erythropoietin
- Anemia
- Kidney Failure, Chronic
- Recombinant Proteins
- Hematinics
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.